We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » ALPHARMA-TEVA NEURONTIN DEAL VIOLATES FDA RULES, PFIZER SAYS
ALPHARMA-TEVA NEURONTIN DEAL VIOLATES FDA RULES, PFIZER SAYS
May 18, 2004
Arguing that drug exclusivity is not a right that can be transferred, Pfizer contends the recent deal between Teva Pharmaceutical and Alpharma to share a portion of Alpharma’s 180-day marketing exclusivity period for a version of Pfizer’s epilepsy drug Neurontin (gabapentin) violates federal drug patent laws.